Mizuho Maintains Buy on Terns Pharma, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh has maintained a Buy rating on Terns Pharma (NASDAQ:TERN) but reduced the price target from $17 to $10.

November 27, 2023 | 4:36 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Mizuho analyst maintains a Buy rating on Terns Pharma but lowers the price target from $17 to $10.
The reduction in the price target from $17 to $10 by a Mizuho analyst, despite maintaining a Buy rating, could lead to a negative perception among investors and potentially cause a short-term decline in TERN's stock price. The lowered target suggests a reassessment of the company's future growth or profitability, which may be factored into the stock's trading price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100